{"id":"NCT01335698","sponsor":"Bristol-Myers Squibb","briefTitle":"Phase IIIB Study Evaluating the Effects of Atazanavir Powder With Ritonavir in HIV-infected Pediatric Patients","officialTitle":"A Prospective Single Arm, Open-label, International, Multicenter Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Atazanavir (ATV) Powder Boosted With Ritonavir (RTV) With an Optimized NRTI Background Therapy, in Human Immunodeficiency Virus (HIV) Infected, Antiretroviral, Naive and Experienced Pediatric Subjects From 3 Months to Less Than 11 Years.(Pediatric Atazanavir International Clinical Evaluation: the PRINCE II Study)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-05-27","primaryCompletion":"2014-09-10","completion":"2018-01-22","firstPosted":"2011-04-14","resultsPosted":"2016-02-08","lastUpdate":"2018-11-09"},"enrollment":160,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["HIV"],"interventions":[{"type":"DRUG","name":"Atazanavir Sulphate","otherNames":["Reyataz","BMS-232632"]},{"type":"DRUG","name":"Ritonavir","otherNames":["Norvir"]}],"arms":[{"label":"Stage 1: Atazanavir + Ritonavir","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to describe the safety, efficacy, and pharmacokinetics of a regimen of atazanavir powder boosted with ritonavir and an optimized dual nucleoside reverse transcriptase inhibitor in pediatric patients aged â‰¥3 months to \\<11 years.","primaryOutcome":{"measure":"Number of Participants Who Died and With Adverse Events (AEs) Leading to Discontinuation, Hyperbilirubinemia, Jaundice, First-degree Arterioventricular Block, Tachycardia, and Rash on ATV Powder","timeFrame":"Day one to week 300 (approximately 22-Jan-2018)","effectByArm":[{"arm":"Atazanavir, 150 mg + Ritonavir, 80 mg (Weight: 5 to <10 kg)","deltaMin":0,"sd":null},{"arm":"Atazanavir, 200 mg + Ritonavir, 80 mg (Weight: 5 to <10 kg)","deltaMin":0,"sd":null},{"arm":"Atazanavir, 200 mg + Ritonavir, 80 mg (Weight: 10 to <15 kg)","deltaMin":0,"sd":null},{"arm":"Atazanavir, 250 mg + Ritonavir, 80 mg (Weight: 15 to <25 kg)","deltaMin":0,"sd":null},{"arm":"Atazanavir, 300 mg + Ritonavir, 100 mg (Weight: 25 to <35 kg)","deltaMin":0,"sd":null}],"pValues":[]},"eligibility":{"minAge":"3 Months","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":8},"locations":{"siteCount":32,"countries":["United States","Argentina","Brazil","Chile","Mexico","Poland","Romania","Russia","South Africa","Spain","United Kingdom"]},"refs":{"pmids":[],"seeAlso":["http://bms.com/studyconnect/Pages/home.aspx","http://www.bms.com/clinical_trials/Pages/Investigator_inquiry_form.aspx"]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":23},"commonTop":["Gastroenteritis","Upper respiratory tract infection","Vomiting","Pyrexia","Cough"]}}